DNMT3A and postmenopausal osteoporosis: Zengxin Jiang et al. (2024) also reported a novel therapeutic strategy to prevent and treat postmenopausal osteoporosis by inhibiting the ferroptosis of osteocytes via the NRF2/Dnmt3a/RANKL axis.